Interleukin Genetics Licenses its PST® Genetic Test to OralDNA Labs
News Aug 18, 2008
The PST® Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss.
Under the terms of the agreement, OralDNA will receive a non-exclusive license from Interleukin Genetics to market, sell and distribute Interleukin Genetics' proprietary PST® Genetic Test to dental practices within the United States.
OralDNA will pay Interleukin Genetics a set fee per test for all tests sold by OralDNA and is responsible for all costs it incurs for marketing such tests. Patients will be asked in the informed consent if they would like to receive additional testing services, other than the PST® Genetic Test, provided by Interleukin Genetics.
Lewis H. Bender, Chief Executive Officer of Interleukin Genetics, commented, "We are pleased to have entered into this license agreement for OralDNA to market our PST® Genetic Test as a determinant of risk for periodontal disease.”
Bende continued, “We believe that this relationship will allow our sales of this important product to grow with a sales force that specifically targets dental practices. In addition, we expect that this agreement with OralDNA Labs will enable our core strategy of growth through partnerships and should allow Interleukin Genetics to build a customer base to provide additional test services."